Posted by Michael Wonder on 25 Jul 2017
PBAC to conduct stakeholder forum on the post-market review of the use of biologics in the treatment of severe chronic plaque psoriasis
25 July 2017 - A stakeholder forum will be held for the post-market review of the use of biologics in the treatment of severe chronic plaque psoriasis on 20 October 2017 in Melbourne.
The review was recommended by the PBAC at its December 2015 meeting and approved by the Minister for Health on 7 April 2016.
At its August 2016 meeting, the PBAC endorsed the final terms of reference and altered the name of the review from ‘bDMARDs’ to ‘biologics’ in response to stakeholders’ comments that these drugs are not anti-rheumatic drugs, but biological drugs for the treatment of psoriasis and psoriatic arthritis.
Consumers of biological medicines listed on the PBS for severe chronic plaque psoriasis, clinicians and pharmaceutical sponsors have been invited to participate.
